22 May 2025
22 May 2025
Potential US pharma import tariffs could raise prices, stifle innovation, and revolutionise how the industry produces drugs.
After the FDA asked for more clinical data this month, Moderna has decided to resubmit the BLA later this year.
The lower out-of-pocket costs come at a time of governmental scrutiny on prescription drug prices in the US.
The decision to register the therapy was supported by data from the Phase III TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6 trials.
The partnership is poised to increase patient impact, especially for those who would benefit from enhanced care co-ordination.
GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better outcomes.
Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary for response.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
